echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Drugs Articles > Consino Bio-New Crown Vaccine enters Phase III clinical trials.

    Consino Bio-New Crown Vaccine enters Phase III clinical trials.

    • Last Update: 2020-09-27
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    On September 2, 2020, Consino Bio announced that it had begun a Phase III clinical trial of the new coronavirus vaccine (Adenovirus 5 vector) ("Ad5-nCoV").
    signed an agreement with NPO Petrovax Pharm, LLC ("Petrovax") under which the company and Petrovax will jointly advance phase III clinical trials of Ad5-nCoV in Russia.
    and Petrovax have received applications from the Ministry of Health of the Russian Federation for approval of the clinical trial of Ad5-nCoV and have started phase III clinical trials of Ad5-nCoV in Russia.
    addition, the company is currently promoting the International Multi-Center Phase III clinical trial of Ad5-nCoV and plans to conduct Phase III clinical trials of Ad5-nCoV in several countries.
    .
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.